AXNX - Spark Newswire

1 minute read

News

Axonics Expands Sacral Neuromodulation Intellectual Property Portfolio

Today, 6:39 AM

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months,

AXNX

1 minute read

Axonics Priced 1.75M Share Public Offering of Common Stock; Price Not Mentioned in PR

By Charles Gross

August 3, 4:54 AM

Axonics, Inc. (Nasdaq: AXNX) ("Axonics"), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock.

AXNX

1 minute read

Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance

By Vandana Singh

August 2, 1:58 PM

Axonics Inc (NASDAQ:AXNX) reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million.…

AXNX

1 minute read

Analyst Ratings

What 9 Analyst Ratings Have To Say About Axonics

By Benzinga Insights

August 2, 1:05 PM

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

AXNX

1 minute read

Analyst Ratings

Morgan Stanley Maintains Overweight Rating for Axonics: Here’s What You Need To Know

By Benzinga Insights

August 2, 12:20 PM

Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at $70.46 per share. A move to $80.00 would account for a 13.54% increase from the current share price.

AXNX

1 minute read

Truist Securities Maintains Buy on Axonics, Raises Price Target to $85

By Benzinga Newsdesk

August 2, 9:26 AM

Truist Securities analyst Richard Newitter maintains Axonics (NASDAQ:AXNX) with a Buy and raises the price target from $75 to $85.

AXNX

1 minute read

Morgan Stanley Maintains Overweight on Axonics, Raises Price Target to $80

By Benzinga Newsdesk

August 2, 8:28 AM

Morgan Stanley analyst Cecilia Furlong maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $73 to $80.

AXNX

1 minute read

Earnings

Recap: Axonics Q2 Earnings

By Benzinga Insights

August 1, 5:29 PM

Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by 12.96%, reporting an EPS of $-0.47 versus an estimate of $-0.54.

AXNX